Atlas-incubated Vima launches with $60M: Venture Report

A syndicate led by Atlas Venture launched a new start-up addressing movement disorders, while two other companies garnered nine-figure venture rounds to fuel their clinical plans.

Cambridge, Mass.-based Vima Therapeutics will have $60 million in series A funding to continue clinical development of VIM0423 to treat dystonia. The oral molecule targets muscarinic cholinergic receptors in the brain and was designed with tolerability in mind; the company said it could be a first-in-class therapy for the indication. VIM0423 is in Phase I testing, with a Phase II trial due to begin in 4Q25...